JAOA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

JAOA • Vol 109 • No 6_suppl_2 • June 2009 • 13-17
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oxman, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oxman, M. N.

Herpes Zoster Pathogenesis and Cell-Mediated Immunity and Immunosenescence

 Michael N. Oxman, MD

Dr Oxman discloses that he is the National Chairman of The Shingles Prevention Study and its substudies, which have been supported, in part, by grants from Merck & Co, Inc, to the VA (Veterans Affairs) Cooperative Studies Program, the VA San Diego Medical Research Foundation, and the VA Connecticut Research and Education Foundation.

Address correspondence to Michael N. Oxman, MD, Professor of Medicine and Pathology, University of California, San Diego, Staff Physician (Infectious Diseases), VA San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA 92161-0001. E-mail: mnoxman{at}ucsd.edu

Herpes zoster, or shingles, is a localized disease characterized by unilateral radicular pain and a vesicular rash limited to the area of skin innervated by a single dorsal root or cranial sensory ganglion. Whereas varicella, or chickenpox, results from primary exogenous varicella-zoster virus (VZV) infection, herpes zoster is caused by reactivation of endogenous VZV that has persisted in latent form within sensory ganglia following an earlier episode of chickenpox. In contrast to recurrent herpes simplex, herpes zoster is commonly associated with severe pain: prodromal pain often precedes the rash by several days; pain usually accompanies the dermatomal rash of herpes zoster; and clinically significant pain and allodynia may persist for weeks, months, or even years after the herpes zoster rash has healed, a debilitating complication known as postherpetic neuralgia (PHN). The incidence and severity of herpes zoster and PHN increase with age in association with an age-related decline in cell-mediated immunity to VZV. The Shingles Prevention Study—a randomized double-blinded placebo-controlled trial—sought to evaluate the capacity of a live attenuated VZV vaccine to protect older adults from herpes zoster and PHN by boosting their waning cell-mediated immunity to VZV. The study demonstrated that the zoster vaccine produced significant reductions in the incidence of herpes zoster, in the burden of illness caused by herpes zoster, and in the incidence of PHN.




This article has been cited by other articles:


Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
B. A. Weaver
Herpes Zoster Overview: Natural History and Incidence
J Am Osteopath Assoc, June 1, 2009; 109(6_suppl_2): S2 - S6.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
K. P. High
Overcoming Barriers to Adult Immunization
J Am Osteopath Assoc, June 1, 2009; 109(6_suppl_2): S25 - S28.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Osteopathic Association.